anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
According to the World Health Organization (WHO), epilepsy afflicts more than 50 million people worldwide. Older antiepileptic drugs are still commonly used, despite a diverse range of side effects. New AEDs approved since the early 1990s have shown an improved tolerability profile. Nonetheless, approximately 30% of patients, particularly those with partial onset seizures, are not well controlled even on the newer treatments or they experience significant side effects secondary to treatment. Therefore, the development of new drugs with effectiveness or safety and tolerability advantages over currently marketed antiepileptic drugs is needed. This is a randomized (study medication assigned by chance), double-blind (neither the physician nor the patient knows the name of the assigned study medication), placebo-controlled, parallel-group, multicenter study. The study has 3 phases: an 8-week pretreatment phase including screening and a baseline period, a 14-week double blind treatment phase, including a 2-week titration period and a 12-week maintenance period, and a 4 week posttreatment phase. During the 56-day baseline period, patients will be required to have at least 6 partial onset seizures, no more than \>= 100 partial onset seizures per 28 days, and no seizure-free period for more than 3 weeks to be eligible to enter the double-blind treatment phase of the study. During the double-blind treatment phase of study CARISEPY3013, patients will be randomly assigned to receive 800 mg/day carisbamate, 1,200 mg/day carisbamate, or placebo for 14 weeks. The total duration of study CARISEPY3013 is approximately 26 weeks for each subject. Patients who complete the double-blind treatment phase will be eligible to enter the separate extension study CARISEPY3014. Safety assessments include the monitoring of the frequency, severity, and timing of adverse events, clinical laboratory test results, 12-lead electrocardiogram (ECG) recordings, vital signs measurements, physical and neurologic examinations, the Physician Withdrawal Checklist for symptoms of withdrawal for those patients who taper and/or discontinue study drug, and pregnancy tests for females of childbearing potential. Assessments of effectiveness include seizure counts at every visit and the Quality of Life in Epilepsy-31 Patient Inventory questionnaire. A Medical Resource utilization questionnaire will be used to obtain cost-effectiveness information on carisbamate. The study hypothesis is that carisbamate is superior to placebo as add-on therapy (i.e., in addition to the current antiepileptic drugs that patients are taking) for the treatment of partial onset seizures in patients with epilepsy. Carisbamate 800 mg/day, 1,200 mg/day, or placebo taken twice daily in 2 equally divided doses, with or without food, and taken with noncarbonated water. A double-dummy design will be used so that all patients will take the same number of active drug and placebo tablets each day during the 14 weeks of the double blind treatment phase. Patients will continue to take a stable dosage or dosages of up to 3 antiepileptic drugs that they are already taking for their seizures during the entire study.
268,719. Merz, F., (trading as Merz & Co.). March 30, 1926, [Convention date]. Ointments. - Water ointments, particularly ointments made up on a basis of tragacanth, glycerine and water are given an unctuous character, similar to that of vaseline ointments, by the addition of a culture of a fermentation fungus such as yeast. According to an example a mixture of rye or wheat flour, maize starch, water, milk, and yeast is allowed to ferment at a moderate temperature and finally to dry at the same temperature. A small proportion of this dry culture is added to tragacanth and the mixture stirred into a solution of glycerine in water. The whole is then gradually heated to boiling point, so as to provide favourable conditions for propagation and ultimate sterilization, and cooled. The basis is suitable for making mercury ointment.
PURPOSE: To provide a halo-aromatic composition for diagnosis which can be prepared in a good yield. CONSTITUTION: This composition contg. radioactive iodine consists of a pharmaceutically-acceptable liquid blend and at least one adjuvant. The composition is produced by a method of producing a chloro-, bromo-, radioactive-bromo-, iodo- and/or radioactive-iodo-aromatic compound or if necessary, a (hetero) aromatic compound contg. at least one additional substituent, by reacting a halogenated or diazonium-substituted compound corresponding to the above compound, and a water-soluble chloride, bromide, radioactive bromide, indide or radioactive iodide, in the presence of a water-soluble acid or copper ions as a catalyst. At this time, this reaction is performed in the presence of at least one reducing agent which is stable in an acidic medium and the amount of which exceeds that of the catalyst.
Tislelizumab 200 mg intravenously (IV) once every 3 weeks (21 days per cycle) until no evidence of continued clinical benefits, unacceptable toxicity, or withdrawal of informed consent at the discretion of the investigator. There were 3 parts in this study: dose verification, pharmacokinetic (PK) sub-study, and indication expansion.
All the tests will be performed using standardised protocols and technical aids. The assessments will be performed in the afternoon (after the daily rehabilitation program). The patients who will be able to perform the 5TSTS will perform that test first. If those patients will bill able to stand up within 30 seconds on each of the five trials, the 30SSTS will be performed next; otherwise, the number of times that the patient was able to complete the transition to the standing position will be recorded and taken as the 30SSTS result. Repetition of the outcome measurements will not serve to simply use the differences as the actual outcomes, but will serve to assess floor effect (the percentage of patients attaining the minimum possible score) on each occasion, to assess repeatability (intra-class correlation between the measurements on two consecutive days), minimal detectable change (calculated from the standard error of measurement, which will be estimated from the correlation between the measurements at the start and after two weeks) and effect size (difference between the mean measurements at the start and after two weeks, divided by the standard deviation at the start). In addition, the repeated measurements will be used to assess concurrent validity in terms of the correlation between the sit-to-stand tests and the walking tests on two occasions (at the start and after two weeks).
A plasma sequestration system having a volume control system is provided.   When a calculated volume of whole blood has been processed, the system switches from a fill to an empty cycle.  The termination point is calculated in advance, based on the desired composition of the collected plasma, thus improving process control and product uniformity.   The system is automated or partially automated using an optical sensor or marker to monitor the volume of packed red blood cells.  When the red cells reach the marker or sensor,  a  signal  is  sent  to  the  control  system which  then calculates the required fill volume.  Processing continues until the calculated fill volume is reached, at which time the system automatically stops the collection cycle.  The system also provides for two speed operation of the centrifuge as a safeguard against foaming which may result in aerosol formation and blood trauma. Foaming is reduced by reducing centrifuge speed as the packed red blood cells approach the stationary deflector in the centrifuge bowl.
Human papillomavirus (HPV) is predominantly associated with HPV-related cancers, however, the precise mechanisms underlying the HPV-host epigenetic architectures in HPV carcinogenesis remain elusive. Here, we employed high-throughput chromosome conformation capture (Hi-C) to comprehensively map HPV16/18-host chromatin interactions. Our study identified the transcription factor Sp1 as a pivotal mediator in programming HPV-host interactions. By targeting Sp1, the active histone modifications (H3K27ac, H3K4me1, and H3K4me3) and the HPV-host chromatin interactions are reprogrammed, which leads to the downregulation of oncogenes located near the integration sites in both HPV (E6/E7) and the host genome (KLF5/MYC). Additionally, Sp1 inhibition led to the upregulation of immune checkpoint genes by reprogramming histone modifications in host cells. Notably, humanized patient-derived xenograft (PDX-HuHSC-NSG) models demonstrated that Sp1 inhibition promoted anti-PD-1 immunotherapy via remodeling the tumor immune microenvironment in cervical cancer. Moreover, single-cell transcriptomic analysis validated the enrichment of transcription factor Sp1 in epithelial cells of cervical cancer. In summary, our findings elucidate Sp1 as a key mediator involved in the programming and reprogramming of HPV-host epigenetic architecture. Inhibiting Sp1 with plicamycin may represent a promising therapeutic option for HPV-related carcinoma.
The invention relates to a cyclic peptide with antibacterial activity and a synthesis method thereof, belonging to the technical field of biological pharmacy. The method adopts the main technical scheme that under the room temperature and slightly alkaline environment, m-dibromide benzyl is used as a micromolecular auxiliary reagent, and the thiol of two cysteine in the linear peptide is subjected to nucleophilic substitution reaction with the thiol, so that the linear peptide is cyclized. The method for cyclizing the linear chain peptide has mild reaction conditions and is easy to realize. The reaction speed is high, the time is short, and the reaction can be finished within 2 hours. The cyclization efficiency can reach more than 90 percent, the total yield of the cyclic peptide can reach more than 60 percent, and the synthesis efficiency of the cyclic peptide is greatly improved. The prepared cyclic peptide has high antibacterial activity.
The invention discloses a taxol nano preparation, a preparation method and application thereof, wherein the taxol nano preparation is prepared by mixing taxol, zein and PEG- b And (3) dissolving the PLA amphiphilic block copolymer in an organic solvent to form a mixed solution serving as a No. 1 stream, taking deionized sterile water as a No. 2 stream, simultaneously injecting the No. 1 stream and the No. 2 stream into a two-channel limited-area opposite-impact mixer for rapid mixing, and collecting the prepared nanoparticle suspension to obtain the mixture containing the taxol nano preparation. The invention utilizes the compatibility of the hydrophobic zein and the taxol, combines the self-assembly characteristic of the zein and the segmented copolymer PEG- b PLA is used as a stabilizer coat to prepare taxol nano particles with improved drug encapsulation efficiency and stability and excellent drug release performance, and the method is simple, convenient, quick and easy to control, and the prepared nano particles have uniform particle size distribution.
Preparation Precautions

Caution should be exercised in handling the aqueous solution. Procedures for proper handling and disposal of anticancer drugs should be utilized. Several guidelines on this subject have been published. 1-4 To minimize the risk of dermal exposure, always wear impervious gloves when handling vials and IV sets containing cisplatin. 

Skin reactions associated with accidental exposure to cisplatin may occur. The use of gloves is recommended. If cisplatin contacts the skin or mucosa, immediately and thoroughly wash the skin with soap and water and flush the mucosa with water. More information is available in the references listed below.

Instructions for Preparation

The aqueous solution should be used intravenously only and should be administered by IV infusion over a 6- to 8-hour period (see DOSAGE AND ADMINISTRATION). 

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

NOTE TO PHARMACIST: Exercise caution to prevent inadvertent cisplatin overdosage. Please call prescriber if dose is greater than 100 mg/m 2 per cycle. Aluminum and flip-off seal of vial have been imprinted with the following statement: 

CALL DR. IF DOSE > 100 MG/M 2/CYCLE.
The embodiment of the invention provides an image processing method, an image processing device and an image processing system. In the method, a target in an original image is determined to generate a labeling result. The labeling result includes the position of the target object in the original image. And generating a plurality of target images of the target object according to the labeling result. Those target images are generated by extracting an image of the target object from the original image and changing the image size of the image of the target object. And combining the corresponding target image and the original image according to the zooming operation. This scaling operation is used to change the image size of the displayed original image. Therefore, the efficiency of inspection and marking can be improved.
Difficulties in social integration pose a major mental health problem for Veterans with schizophrenia. Reviews of the literature indicate that Veterans with schizophrenia have lower marriage rates, fewer friendships, and higher rates of living alone than the general population. Poor social integration is also associated with early mortality. To gain traction on this problem, it will be necessary to find treatments that address key determinants of social integration. Evidence indicates that impairments in cognition and affect are among the key determinants of this area of functioning. Findings from the broader rehabilitation literature support a novel conceptual approach to this problem, namely engagement in physical exercise. Physical exercise is associated with improvements in attention, episodic memory, working memory, speed of processing, and executive control. In addition, physical exercise is associated with increases in positive affect and decreases in negative affect. Findings on the effects of physical exercise on cognition and affect have been reported for normal aging, mild cognitive impairment, neurodegenerative disorders, oncology, and depression, but is an area of investigation relatively new to schizophrenia. The proposed study will include 54 Veterans with schizophrenia or schizoaffective disorder (aged 45-65) who will be matched on baseline levels of cardiorespiratory fitness, and then randomized (2:1) to a walking exercise group (n=36) or a control comparison group (n=18). Veterans in the exercise group will participate in a 12-week, instructor-led, outdoor brisk walking exercise program conducted in small groups (n=6), held 3 times per week, gradually increasing walking time until reaching a maximum of 40-minutes per session. The heart rate of each Veteran will be monitored during the walking sessions to help ensure maintenance of a target peak heart rate of 60% to 70% of the maximum for the individual's age (i.e., 220-age). Veterans in the control group will participate in instructor-led, non-aerobic stretching exercises in small groups (n=6) with the duration, frequency, and total number of sessions matched to the exercise group. Primary outcome measures of cardiorespiratory fitness, cognition, and positive and negative affect of participants in both groups will be measured at baseline and the 12-week end-point assessment.
PURPOSE: An internet phone device including a bio analysis device and a method for remote clinical service using the same are provided to perform clinical service through the internet phone device, thereby performing clinical examination. CONSTITUTION: An internet phone transceives information about medical service or voice signal. A bio analysis device(100a) includes a bio chip analysis device or bio disk drive. A remote medical diagnosis server arbitrates connection between a doctor, hospital server, and the bio analysis device through the internet phone. A tray loads a bio disk or an optical disk. A motor rotates the bio disk or the optical disk.
Participants will receive a fixed dose of RO7616789 intravenously once weekly (QW) per dose level on Day 1, 8, and 15 of each 21-day cycle. In case of toxicity, step-up (single or double) dosing may be explored.
PURPOSE: To obtain a medicinal composition containing a dimethylpolysiloxane in combination with a vehicle or support and having an orally administrable formulation, and effective for treating the ulcerous diseases in the gastrointestinal tracts. CONSTITUTION: This composition contains a dimethylpolysiloxane pref. 100-10,000(esp. 300-3,000)mm<2> .S<-1> in combination with a pharmaceuticlly permissible vehicle or support, having an orally administrable formulation. This dimethylpolysiloxane can be orally administered without bringing about any unprofitable effect over an extended period for the purpose of forming and maintaining a protective layer on human esophagus and gastrointestinal tract, its effect being enhanced by its combination with silica gel. The protective effect afforded by the use of this composition is to diminish the activity of tissue damaging mechanism on one hand, while to revitalize the wall relatively undamaged in association with cell regeneration and ulcer cleanup on the other hand.
Each year more than 40,000 surgical reconstructions of the anterior cruciate ligament (ACL) by ligamentoplasty are performed in France; the rupture being most often the result of sports practice. Following this surgical reconstruction of the ACL, a standardized rehabilitation protocol is carried out by a masseur-physiotherapist. A well-established rehabilitative consensus guides the first phase of the 3 months post-operative and patient compliance is generally excellent. The next phase should allow the return to sport (RTS) by following a continuum according to the objectives of the athlete patient. In this continuum, authors distinguish the return to sports activities in the axis, such as running (RTS1), preparing the return to training (RTS2), and much later will be done by the return to competition (RTS3).RTS2, which is probably the most delicate stage due to the highly variable progression from one patient to another, is generally allowed from the 6th month post-operative, after the realization and validation of a battery of tests assessing the athlete's ability to resume training.Despite this precaution, there is a major risk of new injury (20%), especially in the contralateral knee (12%) requiring new, longer, more restrictive rehabilitation care with an additional 3 to 12 months' incapacity for work or sport.. As the risk of "re-injury" of the knee seems independent of the surgical technique used and the first 3 months of rehabilitation, the rehabilitative management of this phase of 3 to 6 months post-operative appears decisive in the prevention of a new injury. The return to running (in the RTS1) therefore seems a major objective for rehabilitation and will build the necessary foundation for the resumption of the patient's favorite sport, RTS2. However, to allow the return to running, no objective criteria have been validated to date and no consensus is identifiable in the scientific literature. It is the same for his preparation and the gradual resumption of running. Thus, an optimized rehabilitation between the 3rd and 6th month, based on objective evaluations of the patient's functional abilities allowing personalized rehabilitation, including guided and individualized running training, could reduce the risk of new ACL injuries (operated or healthy knee) by better preparing the patient for RTS2: the return to his favorite sport
The New Zealand white rabbit (Oryctolagus cuniculus) is a frequently used surgical model. Pain management after surgery is a critical aspect of animal welfare. Recently, a long-acting buprenorphine formulation (Ethiqa XR; EXR) was approved for use in rats and mice but has not yet been investigated in rabbits. The current study aimed to determine whether a single subcutaneous dose of 0.15mg/kg of EXR could achieve and maintain therapeutic buprenorphine plasma concentrations (0.1ng/mL) for 72h in male and female rabbits. We also evaluated the safety profiles of EXR and the fentanyl patch (FP) by assessing fecal output after surgery, because opioids are known to decrease intestinal motility. Behavior and pain scores were compared for rabbits that received either EXR or the FP after undergoing an annulus puncture procedure to induce osteoarthritis. EXR at 0.15mg/kg SC provided a shorter time to onset and sustained analgesia for 72h in male and female rabbits, whereas the FP provided suboptimal analgesia after 48h. Both EXR and FP reduced fecal output after surgery. Output returned to baseline levels within 72h for the EXR group and remained slightly below baseline at 96h after surgery for the fentanyl group. Grimace pain scores revealed no significant difference between treatment groups. These results suggest that EXR is a safe and effective option for postoperative pain management in rabbits.
BACKGROUND: Among women of reproductive age with inflammatory bowel disease (IBD), we aimed to assess the relationship of hormonal contraceptives (HCs) with IBD-related symptoms, and intestinal inflammation.
METHODS: A nested cohort of women in the longitudinal Manitoba Living with IBD Study, ages 18 to 49, were followed for 1 year, with bi-weekly online surveys. This included a validated measure of disease activity; IBD Symptom Inventory (IBDSI), and stool samples obtained at 3 time-points for assessment of fecal calprotectin (FCAL). Use of HC included oral and vaginal intrauterine devices. Logistic regression analysis was used to assess the association between HC and IBD-related symptoms (IBDSI>14 for Crohn disease, >13 for ulcerative colitis), or inflammation (FCAL>250 ug/g) at any measurement point in the study.
RESULTS: Of 71 women, 17 (24%) reported taking HC in the 1 year period. Adjusting for age, disease type, disease duration, and smoking status, the odds of having increased IBD-related symptoms (IBDSI) during the year were lower for women using HC compared with women not using HC [adjusted odds ratio 0.16, 95% CI, 0.02-0.90]. Conversely, women using HC were more likely to have inflammation during the year [adjusted odds ratio 5.7, 95% CI, 1.23-43.6].
CONCLUSIONS: HC use among women with IBD was associated with a lower likelihood of IBD-related symptoms but a higher likelihood of experiencing intestinal inflammation (FCAL>250 ug/g) over 1 year. Further work is needed to examine this dichotomous result, potentially examining aspects such as duration of HC use, and the types of HC.